Nanobiotix SA Unveils Early Phase‑II Results for Nanoradiation‑Enhanced Lung Cancer Therapy

Nanobiotix SA, the Paris‑based biopharmaceutical company that has positioned itself at the forefront of nanomedicine for oncology, announced that the first‑stage data from its Johnson & Johnson‑sponsored Phase II CONVERGE study will be presented at the European Society for Radiotherapy and Oncology (ESTRO) 2026 conference. The presentation, scheduled as #116 at ESTRO, details early outcomes for JNJ‑1900 (NBTXR3), the company’s first‑in‑class nanoradioenhancer, in patients with stage III inoperable non‑small‑cell lung cancer (NSCLC).

Clinical Context and Study Design

The CONVERGE trial evaluates the safety and antitumor activity of an intratumoral injection of JNJ‑1900 followed by standard chemoradiation and consolidative immunotherapy. Patients enrolled had locally advanced, unresectable NSCLC (stage III). The trial’s design leverages the NanoXray platform, whereby gold nanoparticles are delivered directly into the tumor, amplifying the radiation dose within malignant cells while sparing surrounding healthy tissues.

Early Efficacy Signals

While the detailed quantitative data will be disclosed during the ESTRO presentation, preliminary insights shared by the study investigators suggest a promising radiographic response. Key points include:

  • Radiographic Response Rate: Initial imaging indicates a meaningful proportion of participants achieved partial or complete responses to the combined treatment.
  • Safety Profile: Early safety observations align with the established tolerability of NBTXR3 in earlier trials, with no new or unexpected adverse events reported.
  • Biomarker Correlations: Exploratory analyses are underway to identify potential predictive markers that may help select patients most likely to benefit from the nanoradiation approach.

These results reinforce the hypothesis that nanoparticle‑mediated dose enhancement can potentiate the efficacy of conventional radiotherapy without increasing collateral damage.

Strategic Implications

The presentation of Phase II data marks a critical milestone in Nanobiotix’s development trajectory. A successful outcome could accelerate regulatory discussions and pave the way for broader commercialization of JNJ‑1900, potentially expanding the treatment options for a patient population that currently has limited therapeutic alternatives.

The company’s dual listing on NYSE and Euronext Paris, coupled with a market capitalization exceeding €2.1 billion, reflects robust investor confidence. The 2026‑05‑14 closing price of €43.82 sits comfortably below the 52‑week high of €47.60, suggesting that market participants may be positioning for an upward trajectory once the trial data are fully disclosed.

Looking Ahead

Beyond the ESTRO conference, Nanobiotix has plans to expand the scope of its nanoradiation platform to other tumor types. The company’s broader pipeline includes NBTXR3‑based studies in head‑and‑neck and pancreatic cancers, which will likely be updated in subsequent press releases and scientific meetings.

Investors and clinicians alike will be watching closely as Nanobiotix presents its early Phase II data. The outcome could redefine the landscape of radiotherapy for locally advanced lung cancer and underscore the therapeutic potential of nanotechnology in oncology.